Tradename: DENGVAXIA
Proper Name: Dengue Tetravalent Vaccine, Live
Indication: To include safety and efficacy data that support the use of DENGVAXIA in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
Approval Date: 06/30/2023
Manufacturer: Sanofi Pasteur Inc.
More: https://www.fda.gov/vaccines-blood-biologics/dengvaxia